Taltz (ixekizumab) / Eli Lilly, Japan Tobacco 
Welcome,         Profile    Billing    Logout  
 21 Diseases   26 Trials   26 Trials   3632 News 


12345678910111213...3536»
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
    Journal:  Linear Psoriasis in a Pediatric Patient Successfully Treated With Ixekizumab. (Pubmed Central) -  Nov 17, 2024   
    The lesion showed only mild improvement with topical steroid therapy but exhibited significant clearance with the biologic agent ixekizumab, an IL-17A inhibitor. With limited supporting literature regarding management, this case report illustrates the clinical manifestation, diagnosis, and an effective management strategy for linear psoriasis in a pediatric patient.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Bimzelx (bimekizumab-bkzx) / UCB
    Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review. (Pubmed Central) -  Nov 14, 2024   
    Amongst the biological therapies, bimekizumab and ixekizumab appear to provide the most economic benefit. Finally, new economic studies are needed to enrich knowledge on the economic burden of subgroups of PsA patients as well as early treatment of PsA with new therapies.
  • ||||||||||  Review, Journal:  A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo. (Pubmed Central) -  Nov 13, 2024   
    Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.
  • ||||||||||  Siliq (brodalumab) / Bausch Health, Humira (adalimumab) / AbbVie
    Induction Cost Per Responder of Brodalumab Compared With Other Biologic Therapies for Patients With Moderate to Severe Plaque Psoriasis in Canada () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3175;    
    The CPR was estimated as the drug acquisition costs during the induction period multiplied by the number needed to treat (NNT) for achieving PASI 75, 90, or 100 for the following treatments: adalimumab (innovator and SEB), brodalumab, bimekizumab, certolizumab pegol, etanercept (innovator and SEB), guselkumab, infliximab (innovator and SEB), ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab (innovator and SEB). These results demonstrate that brodalumab has the lowest induction CPR across all PASI outcomes compared to other biologic therapies, including SEB therapies, thus providing the best value for money for patients, prescribers, and payers.
  • ||||||||||  Bimzelx (bimekizumab-bkzx) / UCB
    Cost-Effectiveness Analysis of Bimekizumab in Patients With Active Psoriatic Arthritis (PSA) in Greece () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2791;    
    As only TNFi-experienced patients were included in the analysis, secukinumab 300mg was used to reflect its licensed posology. The analysis suggests that the additional therapeutic benefits of bimekizumab makes it a cost-efficient treatment option, in Greece, despite its incrementally higher costs.
  • ||||||||||  Strategies of Operational Savings in an Integrated Care Clinic for Immune-Mediated Skin Diseases () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2778;    
    The drugs managed were mainly 29.8% omalizumab, 21.8% adalimumab, 16.8% dupilumab, 7.7% ixekizumab, 7.4% guselkumab, 4.9% ustekinumab, 4.2% secukinumab, 2.1% etanercept, 2.1% risankizumab, and 3.2% other drugs. CLIPSO generates a relevant economic impact on the appropriate prescription and scaling of biological therapies for patients with immune-mediated skin diseases.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Evaluating the Effectiveness of Switching Treatments in Chronic Psoriasis: A Targeted Literature Review () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2628;    
    Switching biologic treatments can enhance psoriasis disease control, but it is unclear if this is because of desensitization to the initial treatment or the introduction of newer, more effective treatments. To address this research gap, studies that swap between parallel treatment arms should be conducted to determine the most effective treatment strategy.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
    How Do STC and ML-NMR Compare in Population Adjustment for ITC? Insights and Challenges () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1905;    
    Reproducibility and transparency is potentially a limitation since analysts rarely report steps in detail and precise guidance is limited. A dedicated R package for ML-NMR provides consistency, though users need to be fully aware of what the default options imply for the model.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
    Journal:  New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series. (Pubmed Central) -  Oct 16, 2024   
    Treatment with anti- IL-17a has been approved for ankylosing spondylitis, psoriasis, and psoriatic arthritis, but was not found effective for the treatment of inflammatory bowel disease (IBD). This case series describes four patients with new onset IBD under treatment with an IL-17a inhibitor for a rheumatological or dermatological indication.
  • ||||||||||  Journal:  Patients' Preferences Regarding Modes of Systemic Psoriasis Treatment - A Qualitative Study. (Pubmed Central) -  Oct 9, 2024   
    Five themes resulted from the analysis: patients receiving injectables more frequently discussed the positive impact of the medication on quality of life compared to patients on oral medication; fear of side effects, particularly fear of immunosuppression, is associated with injection medications; avoidance of needles drives patients away from injection medication and towards oral systemic medication; patients prioritize convenience when selecting systemic therapy, though the definition of convenience is subject to perception; and patients value the medication recommendation of the physician, regardless of the route of administration. Improving medication adherence and disease outcomes through individualized treatment plans, with an emphasis on patients' preferences using a shared decision-making approach, may be helpful.
  • ||||||||||  Clinical guideline, Review, Journal:  2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore. (Pubmed Central) -  Oct 7, 2024   
    Therapeutic implica-tions in special populations, such as pregnant/ lactating women, children, the elderly, those undergo-ing surgery and those suffering from specific infections and cancer were addressed. These guidelines were developed for dermatologists, family physicians, rheumatologists and other specialists to support their selection of appropriate management options.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
    Diffuse Lupus Nephritis Secondary to Ixekizumab Therapy: A Case Report and Literature Review (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4387;    
    Lupus nephritis after IL-17 inhibition is not well known or documented as a possible adverse effect, it has been reported before only once after secukinumab therapy (another anti-IL17). To our knowledge this is the the first reported case of drug induced lupus nephritis due to Ixekuzumab.The relationship between IL-17 inhibitors and lupus nephritis not yet well established and Further research are needed.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
    Clinical, Observational data, Journal:  Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. (Pubmed Central) -  Sep 22, 2024   
    To our knowledge this is the the first reported case of drug induced lupus nephritis due to Ixekuzumab.The relationship between IL-17 inhibitors and lupus nephritis not yet well established and Further research are needed. This study confirms the rapid 3-month effectiveness of IXE on joint disease activity-as fast as TNFi and JAKi (cDAPSA), and exceeding IL-12/23i and IL-23i-along with clear benefits to skin.
  • ||||||||||  Review, Journal:  Drugs for plaque psoriasis. (Pubmed Central) -  Sep 21, 2024   
    No abstract available No abstract available
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
    CYTOMEGALOVIRUS-INDUCED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN A CRITICALLY ILL PATIENT WITH PSORIATIC ARTHRITIS (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6553;    
    This case highlights the importance of including HLH on the differential in patients with spondyloarthropathies especially those who are chronically immunosuppressed, who present with pancytopenia and nonspecific symptoms. Early initiation of HLH workup and, if appropriate, empiric treatment, has the potential to reduce mortality in this rare but potentially fatal condition.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
    Journal:  Biologic anti-IL17 drugs in erythrodermic psoriasis. (Pubmed Central) -  Sep 10, 2024   
    Only descriptive analysis was conducted due to the limited number of patients. A satisfactory long-term clinical response without adverse effects was observed in this case series, suggesting the interest of anti-IL17 in EP treatment.
  • ||||||||||  Review, Journal:  Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. (Pubmed Central) -  Sep 8, 2024   
    A satisfactory long-term clinical response without adverse effects was observed in this case series, suggesting the interest of anti-IL17 in EP treatment. This systematic review provides robust evidence regarding treatment options for individuals with psoriasis and MD, emphasizing the potential benefits of specific drugs in managing both conditions concurrently.